Kobe-Based M's Science To Accelerate Cerebral Infarction Clinical Drug Trials
This article was originally published in PharmAsia News
Executive Summary
Kobe-based clinical stage drug discovery and development venture company, M's Science, announced the allocation of new shares to a third party May 26 in an effort to speed up clinical trials for SA4503. Developed by the company, SA4503 is a drug agent with potential applications for treating cerebral infarction and depression, and currently it is in Phase II trials in Europe. The ¥940 million investment infusion comes from 16 venture capital companies, including Japan Asia Investment Corp, Yasuda Enterprise Development and First Track Initiative. The funds will be used to speed up the trials. (Click here for more - Japanese language
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.